Published in Haemostasis on January 01, 1983
Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology (1999) 5.34
Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis. N Engl J Med (1996) 2.38
Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell (1998) 2.34
Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med (1984) 2.26
False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost (2009) 2.14
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost (1998) 1.71
Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med (1991) 1.56
Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) (1999) 1.54
Point mutations regarded as missense mutations cause splicing defects in the factor XI gene. J Thromb Haemost (2011) 1.46
A plasma protein C activity assay suitable for a clinical laboratory. Its use to measure activity in hereditary and acquired deficiency states. Am J Clin Pathol (1987) 1.44
Age estimates of two common mutations causing factor XI deficiency: recent genetic drift is not necessary for elevated disease incidence among Ashkenazi Jews. Am J Hum Genet (1999) 1.38
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost (1978) 1.30
Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood (1991) 1.28
Inherited platelet disorders. Haemophilia (2012) 1.27
A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel. Thromb Haemost (1984) 1.17
Carrier frequency of the IVS4 + 4 A-->T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood (1995) 1.15
Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med (1970) 1.14
Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood (1985) 1.13
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis (2004) 1.13
Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem (1997) 1.12
The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A (1991) 1.12
Risk factors associated with postpartum ovarian vein thrombosis. Thromb Haemost (1999) 1.11
Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol (1992) 1.09
Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood (1979) 1.07
The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost (2001) 1.06
Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res (1987) 1.06
Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest (1979) 1.04
Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med (1985) 1.04
Abnormal excretion of the isomers of urinary coproporphyrin by patients with Dubin-Johnson syndrome in Israel. Clin Sci (1971) 1.03
Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol (1999) 1.01
Immunological studies in combined factor V and factor VIII deficiency. Br J Haematol (1977) 1.00
Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med (1982) 1.00
Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost (2000) 0.97
Hepatitis A antibody in Israel Defence Forces recruits. J Med Virol (1981) 0.97
Responses of platelets to strains of streptococcus sanguis: findings in healthy subjects, Bernard-Soulier, Glanzmann's, and collagen-unresponsive patients. Thromb Haemost (1987) 0.97
Thrombophilia as a multigenic disorder. Thromb Haemost (1997) 0.97
High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood (1978) 0.96
Mendelian diseases among Roman Jews: implications for the origins of disease alleles. J Clin Endocrinol Metab (1999) 0.95
Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases. Thromb Diath Haemorrh (1975) 0.95
Rare bleeding disorders. Haemophilia (2006) 0.95
Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost (2003) 0.94
Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping. J Clin Invest (1997) 0.94
Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood (1999) 0.94
ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood (1999) 0.93
Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet (1986) 0.93
A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood (1997) 0.93
Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost (2014) 0.93
Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol (1986) 0.92
Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis (1992) 0.92
Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor. J Lab Clin Med (1986) 0.92
Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke (2001) 0.91
Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17. Br J Haematol (1998) 0.91
Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol (1994) 0.90
Serological evidence for hepatitis E virus infection in Israel. J Med Virol (1995) 0.90
A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood (1998) 0.89
ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. Semin Thromb Hemost (1996) 0.89
Combined factor-V and factor-VIII deficiency: report of four cases. Br J Haematol (1969) 0.88
Ethnic communities in Israel: the genetic blood markers of the Babylonian Jews. Am J Phys Anthropol (1978) 0.88
Association between hyperflexibility of the thumb and an unexplained bleeding tendency: is it a rule of thumb? Br J Haematol (1998) 0.87
Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. J Am Coll Cardiol (1990) 0.87
Effects of ADP and ATP on bovine fibrinogen- and ristocetin-induced platelet aggregation in Glanzmann's thrombasthenia. Br J Haematol (1975) 0.87
Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis (1998) 0.86
Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol (1989) 0.86
A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost (2005) 0.86
Ethnic communities in Israel: the genetic blood markers of the Moroccan Jews. Am J Phys Anthropol (1978) 0.86
Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are not protected from atherosclerosis. Circulation (2002) 0.86
A novel Phe171Cys mutation in integrin alpha causes Glanzmann thrombasthenia by abrogating alphabeta complex formation. J Thromb Haemost (2004) 0.86
[Massive sublingual hemorrhage due to coumadin causing suffocation]. Harefuah (1970) 0.86
Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost (1996) 0.86
Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thromb Res (1978) 0.85
Hereditary deficiency of all vitamin K-dependent procoagulants and anticoagulants. Br J Haematol (1990) 0.85
Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Hum Genet (1998) 0.85
Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem (2001) 0.85
Disseminated intravascular coagulation in experimental heatstroke. Thromb Diath Haemorrh (1971) 0.84
Methionine synthase A2756G and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors for idiopathic venous thromboembolism. Hematol J (2001) 0.84